NCT05511025View on ClinicalTrials.gov

Assess the Safety, Tolerability, and Pharmacokinetics of AZD6234 Following Single Ascending Dose Administration to Healthy Subjects Who Are Overweight or Obese

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

September 20, 2022

Primary Completion Date

December 19, 2023

Study Completion Date

December 19, 2023

Conditions
Healthy Participants
Interventions
DRUG

AZD6234

Participants will receive a single dose of AZD6234 as a solution via SC or IV injection

DRUG

Placebo

Participants will receive matching volumes of the placebo as a solution via SC or IV injection

COMBINATION_PRODUCT

Acetaminophen

Participants will receive a single dose of acetaminophen as part of a meal

Trial Locations (2)

21225

Research Site, Brooklyn

91206

Research Site, Glendale

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY